Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting

Reno, Nevada ( -- Lantheus Holdings, Inc., an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that data from the OSPREY pivotal trial has been selected for presentation at the upcoming 2022 American Society for Clinical Oncology Genitourinary (ASCO GU) Meeting, which will be held February 17-19, 2022 in San Francisco, CA.

Presentation details are as follows:

Date & Time: February 17, 2022, 11:30 – 1:00 PM PT and 5:45 – 6:45 PM PT
Session Title: Poster Session A: Prostate Cancer
Title: Piflufolastat F 18-PET/CT in Prostate Cancer (PCa) Patients (Pts): An Analysis of OSPREY (Cohorts A and B) Standardized Uptake Value (SUV) Results Stratified by PSA and Gleason Score (GS)
Presenter: Michael Gorin, M.D., Urology Associates & UPMC Western Maryland
Abstract No: 35

Source: "Information And Resources| Lantheus". 2022. Lantheus.Com.